Abstract: According to the binding mode of rivaroxaban in complex with human factor Xa and the chemical structure of rivaroxaban, we have designed and synthesized the oxazolidinone ether compounds, which have not be reported in literatures. The structures of all the rivaroxaban derivatives synthesized were identified by IR, ¹H NMR and MS. The anti-factor Xa activity of the synthesized compounds was tested. The results showed that all of the tested compounds exhibited some activity, yet were less potent than rivaroxaban.